Online citations, reference lists, and bibliographies.
← Back to Search

Injectable And Topical Neurotoxins In Dermatology: Indications, Adverse Events, And Controversies.

C. Giordano, S. Matarasso, D. Ozog
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The use of neuromodulators for therapeutic and cosmetic indications has proven to be remarkably safe. While aesthetic and functional adverse events are uncommon, each anatomic region has its own set of risks of which the physician and patient must be aware before treatment. The therapeutic usages of botulinum toxins now include multiple specialties and multiple indications. New aesthetic indications have also developed, and there has been an increased utilization of combination therapies to combat the effects of global aging. In the second article in this continuing medical education series, we review the prevention and treatment of adverse events, therapeutic and novel aesthetic indications, controversies, and a brief overview of combination therapies.
This paper references
10.1111/jdv.12278
Botulinum toxin B in the treatment of craniofacial hyperhidrosis
M. Karlqvist (2014)
10.1111/J.1524-4725.2006.32328.X
Eyebrow height after botulinum toxin type A to the glabella.
A. Carruthers (2007)
10.1016/S0733-8635(03)00118-9
Botulinum toxin A in the mid and lower face and neck.
J. Carruthers (2004)
10.1016/j.cps.2011.03.010
An overview of botulinum toxins: past, present, and future.
Todd V. Cartee (2011)
10.3390/toxins8010022
Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients
R. Rostami (2016)
10.1016/j.det.2009.08.013
Complications and their management in cosmetic dermatology.
R. Hirsch (2009)
10.1111/j.1442-2050.2010.01065.x
Botulinum toxin in the treatment of diffuse esophageal spasm.
M. Bashashati (2010)
10.1111/J.1524-4725.2007.33284.X
Clinical Efficacy of Botulinum Toxin Type A Reconstituted and Refrigerated 1 Week before Its Application in External Canthus Dynamic Lines
Mónica Lizarralde (2007)
10.1016/j.urology.2008.08.475
Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Giuseppe Brisinda (2009)
10.1007/s00423-012-0948-2
Botulinum toxin injection versus lateral internal sphincterotomy for the treatment of chronic anal fissure: randomized prospective controlled trial
N. Valizadeh (2012)
10.1111/j.1473-2165.2011.00593.x
Advances in the use of botulinum neurotoxins in facial esthetics
T. Flynn (2012)
10.1111/j.1365-2133.2004.06317.x
The place of botulinum toxin type A in the treatment of focal hyperhidrosis
N. Lowe (2004)
10.1007/s00105-012-2333-z
Botulinumtoxin bei fokaler Hyperhidrose
C. Hosp (2012)
10.1016/j.bone.2011.11.015
Botulinum toxin in masticatory muscles: short- and long-term effects on muscle, bone, and craniofacial function in adult rabbits.
K. Rafferty (2012)
10.1002/mds.22336
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
10.2165/00128071-200506030-00001
Managing Adverse Events Associated with Botulinum Toxin Type A
U. Wollina (2005)
10.1067/MJD.2000.105156
Botulinum toxin type A therapy for palmar and digital hyperhidrosis.
B. A. Solomon (2000)
10.1067/MJD.2002.124070
Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet.
N. Lowe (2002)
10.1097/01.DSS.0000452642.83894.ab
Prospective Randomized Controlled Study to Determine the Effect of Topical Application of Botulinum Toxin A for Crow's Feet After Treatment With Ablative Fractional CO2 Laser
B. Mahmoud (2015)
Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
Irene J Vergilis-Kalner (2011)
10.1007/BF00839206
Treatment of spasmodic torticollis with local injections of botulinum toxin
W. Poewe (2004)
10.1097/DSS.0000000000000303
Consensus Statement Regarding Storage and Reuse of Previously Reconstituted Neuromodulators
M. Alam (2015)
10.1111/dsu.12240
Validated Assessment Scale for Platysmal Bands
Thorin L. Geister (2013)
10.1111/J.1524-4725.2005.31070
Double‐Blind, Randomized, Placebo‐Controlled, Dose‐Response Study of the Safety and Efficacy of Botulinum Toxin Type A in Subjects with Crow's Feet
N. Lowe (2005)
10.1159/000370245
Serious and Long-Term Adverse Events Associated with the Therapeutic and Cosmetic Use of Botulinum Toxin
E. Yiannakopoulou (2015)
10.2340/00015555-1464
Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis.
K. Rosell (2013)
10.1002/MDS.870120637
Idiosyncratic adverse reactions to intramuscular botulinum toxin type a injection
P. Lewitt (1997)
10.1097/01.PRS.0000082203.65641.DD
Botulinum A Exotoxin for the Management of Platysma Bands
A. Matarasso (2003)
10.1016/J.SURVOPHTHAL.2006.10.003
Botulinum toxin in ophthalmology.
J. Dutton (2007)
10.4088/JCP.13m08845
Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.
Michelle Magid (2014)
10.1046/J.1524-4725.2002.02039.X
Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Palmar Hyperhidrosis: A Double‐Blind, Randomized, Placebo‐Controlled Study
N. Lowe (2002)
10.1080/14764170410023767
Botulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing
P. Yamauchi (2004)
10.1111/j.1365-2133.2011.10235.x
Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia
F. Pelletier (2011)
10.1007/s004150050345
Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency
K. Kessler (1999)
10.1016/S0190-9622(98)70242-7
Botulinum toxin therapy for palmar hyperhidrosis.
W. Shelley (1998)
10.1111/J.1524-4725.2006.32333.X
Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines.
A. Carruthers (2007)
10.1016/j.det.2014.06.001
Botulinum toxin for hyperhidrosis of areas other than the axillae and palms/soles.
D. Glaser (2014)
10.1002/lsm.20891
Diode laser hair removal does not interfere with botulinum toxin A treatment against axillary hyperhidrosis
A. Paul (2010)
10.1001/jamafacial.2013.2458
Subcutaneous vs intramuscular botulinum toxin: split-face randomized study.
E. Gordin (2014)
10.1016/S0149-2918(03)90041-5
Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study.
A. Campanati (2003)
10.1111/j.1524-4725.2009.01230.x
Treatment of granulosis rubra nasi with botulinum toxin type A.
T. C. Grazziotin (2009)
Retrospective review of 500 patients treated with abobotulinumtoxinA.
O. Hevia (2010)
10.1001/ARCHDERM.138.4.510
Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial.
M. Alam (2002)
10.1097/PSN.0b013e3181fe99c2
What Are the Necessary Practice Competencies for Two Providers: Dermal Fillers and Botulinum Toxin Type A Injections?
Marcia E Spear (2010)
10.1111/dsu.12405
Diffusion of Two Botulinum Toxins Type A on the Forehead: Double‐Blinded, Randomized, Controlled Study
H. Jiang (2014)
10.1007/s00702-011-0719-1
Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay
D. Dressler (2011)
10.1097/01.PRS.0000153236.79775.A0
The Use of Botulinum Toxin Type A in Aesthetic Mandibular Contouring
N. Kim (2005)
10.1007/s00702-010-0529-x
Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm
B. Wabbels (2010)
10.1016/J.FSC.2006.11.002
Hyaluronic acid fillers: Restylane and Perlane.
F. Brandt (2007)
10.1016/j.toxicon.2011.05.012
Characterization of diffusion and duration of action of a new botulinum toxin type A formulation.
H. F. Stone (2011)
10.1111/j.1524-4725.2010.01711.x
Efficacy and Safety Evaluation of a Novel Botulinum Toxin Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines
F. Brandt (2010)
10.1111/j.1524-4725.2011.01952.x
Survey of Regional Laser Centers: A Minnesota Perspective
Susan E. Walgrave (2011)
10.1080/14764170701545657
The ‘Nefertiti lift’: A new technique for specific re‐contouring of the jawline
Phillip M Levy (2007)
10.1097/ICO.0000000000000482
Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm
Alime Gunes (2015)
10.1111/j.1524-4725.2009.01235.x
Randomized, Placebo‐Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety
F. Brandt (2009)
10.1111/j.1524-4725.2011.02109.x
Botulinum Toxin for the Treatment of Menopausal Hot Flushes: A Pilot Study
M. Y. Odo (2011)
10.1097/DSS.0000000000000357
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines
J. Carruthers (2015)
10.1017/S0022215100109788
Pharyngeal paralysis due to botulinum toxin injection.
C. E. Koay (1989)
10.1016/S0161-6420(96)30644-1
The use of botulinum A toxin to ameliorate facial kinetic frown lines.
J. Foster (1996)
10.1097/DSS.0000000000000365
Impact of Postreconstitution Room Temperature Storage on the Efficacy of IncobotulinumtoxinA Treatment of Dynamic Lateral Canthus Lines
D. J. Soares (2015)
10.1111/j.1365-2133.2003.05620.x
A double‐blind, randomized, comparative study of Dysport® vs. Botox® in primary palmar hyperhidrosis
M. Simonetta Moreau (2003)
[Severe respiratory failure after injection of botulinum toxin: case report and review of the literature].
L. Nong (2008)
10.1097/01.DSS.0000452645.76270.88
Fields of Muscular and Anhidrotic Effects of 2 Botulinum Toxin-A Commercial Preparations: A Prospective, Double-Blind, Randomized, Multicenter Study
D. Hexsel (2015)
10.7205/MILMED-D-13-00477
OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report.
A. Robinson (2014)
10.2147/CIA.S9338
Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction
K. D. De Boulle (2010)
10.1212/WNL.0b013e318232ab65
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
R. Lipton (2011)
10.1016/S0190-9622(99)70202-1
Fixed drug eruption caused by lactose in an injected botulinum toxin preparation.
N. Cox (1999)
10.4103/0974-2077.69019
The Use of Botulinum Toxin as Primary or Adjunctive Treatment for Post Acne and Traumatic Scarring
G. Goodman (2010)
10.1016/j.eururo.2013.10.033
An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
A. Mangera (2014)
10.1111/head.12236
Roadblock to the Only FDA‐Approved Treatment for Chronic Migraine
J. Charles (2014)
10.1111/j.1524-4725.2010.01710.x
Antibody‐Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications
D. Dressler (2010)
10.1097/PRS.0000000000001841
Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck—Jawline Contouring/Platysma Bands/Necklace Lines
Phillip M Levy (2015)
10.1111/J.1524-4725.2004.30255.X
Botulinum Toxin A for Aesthetic Contouring of Enlarged Medial Gastrocnemius Muscle
H. Lee (2004)
10.1007/s00266-004-0062-0
Evaluating Effects of Preservative-Containing Saline Solution on Pain Perception During Botulinum Toxin Type-A Injections at Different Locations: A Prospective, Single-Blinded, Randomized Controlled Trial
N. Sarıfakioğlu (2004)
10.1097/DSS.0000000000000262
A Prospective Rater- and Subject-Blinded Study Comparing the Efficacy of IncobotulinumtoxinA and OnabotulinumtoxinA to Treat Crow's Feet: A Clinical Crossover Evaluation
Gabriele Muti (2015)
10.1111/wrr.12204
Early postoperative treatment of thyroidectomy scars using botulinum toxin: A split‐scar, double‐blind randomized controlled trial
Y. Kim (2014)
10.1007/s00702-013-1074-1
Onabotulinumtoxin type A (Botox®) versus Incobotulinumtoxin type A (Xeomin®) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial
A. Campanati (2013)
10.1097/SAP.0000000000000625
Donor Site Aesthetic Enhancement With Preoperative Botulinum Toxin in Forehead Flap Nasal Reconstruction
J. Zelken (2016)
10.1097/DSS.0000000000000223
The Risorius Muscle: Anatomic Considerations With Reference to Botulinum Neurotoxin Injection for Masseteric Hypertrophy
Jung-hee Bae (2014)
10.1007/s12640-015-9565-5
Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis
M. Fabbri (2015)
10.1016/J.FSC.2006.12.001
Botulinum toxins for facial wrinkles: beyond glabellar lines.
S. Dayan (2007)
10.1111/j.1524-4725.2010.01704.x
Effect of Botulinum Toxin Type A Injection on Lower Facial Contouring Evaluated Using a Three‐Dimensional Laser Scan
W. H. Shim (2010)
10.1136/jnnp.72.4.459
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia
D. Ranoux (2002)
10.1097/00006534-199404001-00003
Aesthetic Indications for Botulinum Toxin Injection
B. Guyuron (1994)
10.1097/01.prs.0000209944.45949.d1
Use of Botulinum Toxin Type A to Prevent Widening of Facial Scars
A. M. Wilson (2006)
10.1016/j.det.2014.06.012
Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis.
Tessa Weinberg (2014)
10.1111/j.1468-1331.2009.02877.x
Routine use of Xeomin® in patients previously treated with Botox®: long term results
D. Dressler (2009)
10.1046/J.1524-4725.2002.01116.X
Botulinum Toxin A: Successful Décolleté Rejuvenation
P. Becker-Wegerich (2002)
10.1046/j.1365-2230.2003.01379.x
Successful use of Botulinum toxin‐A for the treatment of neck and anterior chest wall flushing
A. Sterodimas (2003)
10.1136/jnnp.51.7.920
Botulinum toxin in spasmodic torticollis.
R. Stell (1988)
10.1111/dsu.12175
Evaluation of Self‐Esteem and Depression Symptoms in Depressed and Nondepressed Subjects Treated with OnabotulinumtoxinA for Glabellar Lines
D. Hexsel (2013)
10.1097/PRS.0b013e31816de8d0
Advances in Facial Rejuvenation: Botulinum Toxin Type A, Hyaluronic Acid Dermal Fillers, and Combination Therapies–-Consensus Recommendations
J. Carruthers (2008)
10.1073/PNAS.96.6.3200
Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.
A. de Paiva (1999)
10.1097/DSS.0000000000000159
Injecting Botulinum Toxin at Different Depths Is Not Effective for the Correction of Eyebrow Asymmetry
Jason R Sneath (2015)
10.1002/ana.21427
Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain
D. Ranoux (2008)
10.1016/j.det.2011.08.009
Needs assessment for cosmetic dermatologic surgery.
M. Alam (2012)
10.1111/j.1524-4725.2011.01984.x
Practice Models and Roles of Physician Extenders in Dermatologic Surgery
Emily P. Tierney (2011)
10.1111/j.1468-1331.2011.03559.x
Five‐year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins
D. Dressler (2012)
10.1001/archderm.144.12.1657
Intrafollicular orifice injection technique for botulinum toxin type A.
T. Lewis (2008)
10.1111/j.1524-4725.1998.tb04103.x
Cosmetic Use of Botulinum A Exotoxin for the Aging Neck
F. Brandt (1998)
Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence.
R. Jandhyala (2012)
10.1111/j.1524-4725.2012.02456.x
OnabotulinumtoxinA Dose‐Ranging Study for Hyperdynamic Perioral Lines
J. Cohen (2012)
10.31525/ct1-nct04249687
Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines.
R. Glogau (2012)
10.1111/J.1524-4725.1992.TB03295.X
Treatment of glabellar frown lines with C. botulinum-A exotoxin.
J. Carruthers (1992)
10.2147/CIA.S18997
Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
Gabriele Stengel (2011)
10.1520/JFS2004196
Fatal case of BOTOX-related anaphylaxis?
M. Li (2005)
10.1136/bmjopen-2011-000646
Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins—a single cohort 4-year follow-up study
H. Hefter (2012)
10.1177/019459989310800205
Crystalline Preparation of Botulinum Toxin Type a (Botox): Degradation in Potency with Storage
M. Gartlan (1993)
10.1016/S0190-9622(96)90016-X
Botulinum A exotoxin use in clinical dermatology.
A. Carruthers (1996)
10.2165/00128071-200910020-00002
Botulinum Toxin for Hyperhidrosis
A. Grunfeld (2009)
10.1016/J.CLINDERMATOL.2003.12.026
Contraindications and complications with the use of botulinum toxin.
A. Klein (2004)
10.1093/asj/sju072
Absence of bacterial or fungal growth in vials of reconstituted botulinum toxin type A after storage.
T. Osaki (2015)
10.1111/dsu.12247
Botulinum toxin injection for salivary gland enlargement evaluated using computed tomographic volumetry.
G. Y. Bae (2013)
10.1016/S0190-9622(96)90682-9
Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique.
N. Lowe (1996)
10.1111/dsu.12072
Efficacy and Safety of a Novel Botulinum Toxin Type A Product for the Treatment of Moderate to Severe Glabellar Lines: A Randomized, Double‐Blind, Active‐Controlled Multicenter Study
C. H. Won (2013)
10.1111/j.1524-4725.2009.01158.x
Blind Multicenter Study of the Efficacy and Safety of Injections of a Commercial Preparation of Botulinum Toxin Type A Reconstituted up to 15 Days Before Injection
D. Hexsel (2009)
10.1097/01.PRS.0000144795.76040.D3
Consensus recommendations on the use of botulinum toxin type a in facial aesthetics.
J. Carruthers (2004)
10.1111/j.1524-4725.2011.02068.x
A Two‐Phase, Retrospective Analysis Evaluating Efficacy of and Patient Satisfaction with AbobotulinumtoxinA Used to Treat Dynamic Facial Rhytides
Monika G. Kiripolsky (2011)
10.1016/J.SDER.2005.04.006
Accreditation and certification in dermatologic surgery.
S. Nestler (2005)
10.2147/CCID.S26550
Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice
W. Prager (2012)
10.1016/J.FSC.2006.10.006
Fillers in the periorbital complex.
J. C. Finn (2007)
10.1007/s00266-014-0367-6
Are Nurse Injectors the New Norm?
Kevin H. Small (2014)
10.1038/ajg.2014.138
EUS-Guided Botulinum Toxin Injection of the Internal Anal Sphincter in Anorectal Outlet Obstruction
Arvind J. Trindade (2014)
10.1001/jama.2015.2996
Achalasia: a systematic review.
J. Pandolfino (2015)
10.1046/j.1365-2133.1997.d01-1233.x
Double‐blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms
P. Schnider (1997)
10.1111/dsu.12147
The Convergence of Medicine and Neurotoxins: A Focus on Botulinum Toxin Type A and Its Application in Aesthetic Medicine—A Global, Evidence‐Based Botulinum Toxin Consensus Education Initiative: Part I: Botulinum Toxin in Clinical and Cosmetic Practice
A. Carruthers (2013)
10.1111/j.1526-4637.2010.01003.x
Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia.
L. Xiao (2010)
10.1016/j.bjps.2007.11.047
Atrophy of the intrinsic musculature of the hands associated with the use of botulinum toxin-A injections for hyperhidrosis: a case report and review of the literature.
G. Glass (2009)
10.1111/j.1526-4610.2004.04058.x
Hourglass Deformity After Botulinum Toxin Type A Injection
B. Guyuron (2004)
10.1016/j.fsc.2013.07.008
Complications from toxins and fillers in the dermatology clinic: recognition, prevention, and treatment.
S. Dayan (2013)
10.1016/S0163-7258(96)00091-5
Botulinum toxin as a therapeutic agent.
J. Tsui (1996)
10.1016/J.JAAD.2004.08.024
Treatment of facial chromhidrosis with botulinum toxin type A.
S. Matarasso (2005)
10.1007/s00702-014-1165-7
IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®)
D. Dressler (2014)
10.1001/jamadermatol.2013.6440
Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial.
D. Hexsel (2013)
10.1016/j.asj.2008.03.003
Nonsurgical reshaping of the lower face.
S. Liew (2008)
10.1097/01.DSS.0000452649.99141.69
Fields of Anhidrotic Effects of AbobotulinumtoxinA in Patients With Compensatory Hyperhidrosis
D. Hexsel (2015)
10.3390/toxins5040821
Hyperhidrosis: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum Toxins
Amanda-Amrita D. Lakraj (2013)
10.1111/dsu.12125
Muscle Atrophy Beyond the Clinical Effect After a Single Dose of OnabotulinumtoxinA Injected in the Procerus Muscle: A Study with Magnetic Resonance Imaging
I. Koerte (2013)
10.1016/j.jaad.2010.02.053
Gummy smile and botulinum toxin: a new approach based on the gingival exposure area.
Rosemarie Mazzuco (2010)
10.1097/DSS.0000000000000646
Prospective Randomized Split-Face Comparative Study Between Topical Botulinum Toxin A Surface Application and Local Injection for Crow's Feet
B. Mahmoud (2016)
10.1136/jnnp.33.1.40
Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles.
L. Duchen (1970)
10.1111/dsu.12148
The Convergence of Medicine and Neurotoxins: A Focus on Botulinum Toxin Type A and Its Application in Aesthetic Medicine—A Global, Evidence‐Based Botulinum Toxin Consensus Education Initiative: Part II: Incorporating Botulinum Toxin into Aesthetic Clinical Practice
J. Carruthers (2013)
10.1111/J.1524-4725.2006.32372.X
Successful use of botulinum toxin a for the treatment of neck and anterior chest wall flushing.
A. B. Alexandroff (2006)
10.1097/AJP.0b013e31827a72d2
Botulinum Toxin A in Postherpetic Neuralgia: A Parallel, Randomized, Double-Blind, Single-Dose, Placebo-controlled Trial
Z. Apalla (2013)
10.1007/s00105-012-2333-z
[Botulinum toxin in focal hyperhidrosis. An update].
C. Hosp (2012)
10.1016/j.rehab.2015.06.002
Muscle structure and stiffness assessment after botulinum toxin type A injection. A systematic review.
L. Mathevon (2015)
10.2165/11530110-000000000-00000
Botulinum Toxin
T. Flynn (2010)
10.1001/archfacial.2008.538
Pulsed-dye laser for treating ecchymoses after facial cosmetic procedures.
R. Defatta (2009)
10.1111/j.1479-828X.2004.00163.x
Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles
S. Jarvis (2004)
10.1016/j.bjps.2012.09.012
Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study.
M. Ziade (2013)
10.1016/j.jns.2015.01.032
Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin®) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport®)
Christoph Kamm (2015)
10.1001/jamadermatol.2014.2494
Multicenter prospective cohort study of the incidence of adverse events associated with cosmetic dermatologic procedures: lasers, energy devices, and injectable neurotoxins and fillers.
M. Alam (2015)
10.1097/IOP.0b013e31815793b7
Efficacy of Fresh Versus Refrigerated Botulinum Toxin in the Treatment of Lateral Periorbital Rhytids
J. Hui (2007)
10.4065/81.8.1023
Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study.
H. Gassner (2006)
10.1046/j.1468-3083.2001.00350.x
Botulinum toxin A for palmar hyperhidrosis
U. Wollina (2001)
10.1111/j.1524-4725.1996.tb00569.x
Cosmetic Denervation of the Muscles of Facial Expression with Botulinum Toxin A Dose‐Response Study
A. García (1996)
Molecular biology of Clostridial toxins: expression of mRNAs encoding tetanus and botulinum neurotoxins in Aplysia neurons.
S. Mochida (1990)
10.1097/00006534-200003000-00046
Temporal Brow Lift Using Botulinum Toxin A
M. Ahn (2000)
10.1097/PRS.0000000000000589
Anatomical Considerations Regarding the Location and Boundary of the Depressor Anguli Oris Muscle with Reference to Botulinum Toxin Injection
You-Jin Choi (2014)
10.1111/j.1468-3083.2012.04681.x
RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator‐blind, randomized, pilot study
D. Lee (2013)
10.1136/bmjopen-2011-000694
Evaluating the travel, physical activity and carbon impacts of a ‘natural experiment’ in the provision of new walking and cycling infrastructure: methods for the core module of the iConnect study
D. Ogilvie (2012)
10.1007/PL00007813
Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm
W. Jost (2001)
10.1046/J.1524-4725.2003.29017.X
Comparison of Botulinum Toxin Types A And B: A Bilateral and Double‐Blind Randomized Evaluation in the Treatment of Canthal Rhytides
S. Matarasso (2003)
10.2340/00015555-2093
Regional diffusion of botulinum toxin in facial muscles: a randomised double-blind study and a consideration for clinical studies with split-face design.
A. Punga (2015)
10.1111/J.1526-4637.2006.00100.X
Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia.
Hsu-Tang Liu (2006)
10.1016/0039-6257(91)90207-V
Botulinum A toxin (Oculinum) in ophthalmology.
M. Osako (1991)
10.1111/J.1524-4725.2004.30017.X
Botulinum Toxin for the Treatment of Facial Flushing
Melanie Yuraitis (2004)
10.1097/PRS.0000000000001438
Effect of Botulinum Toxin Type A on Differentiation of Fibroblasts Derived from Scar Tissue
Hii Sun Jeong (2015)
10.1111/j.1524-4725.2010.01798.x
Comparison of Two Botulinum Toxin Type A Preparations for Treating Crow's Feet: A Split‐Face, Double‐Blind, Proof‐of‐Concept Study
W. Prager (2010)
10.1016/j.ajodo.2007.04.033
Botulinum toxin type A (Botox) for the neuromuscular correction of excessive gingival display on smiling (gummy smile).
Mario Junior Alves Polo (2008)
10.1111/bjd.12568
Botulinum toxin for focal hyperhidrosis of the face
S. George (2014)
Efficacy and safety of IncobotulinumtoxinA for the treatment of platysmal bands of the aging neck: an open-label, prospective pilot study.
E. Gubanova (2013)
Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study.
Orlando Oliveira de Morais (2012)
10.1016/J.JAAD.2013.06.009
Management of facial erythema of rosacea: What is the role of topical α-adrenergic receptor agonist therapy?
James Q. Del Rosso (2013)
10.1016/J.JAAD.2006.01.019
Sterility assessment of multiple use botulinum A exotoxin vials: a prospective simulation.
M. Alam (2006)
10.1136/jnnp.64.1.6
A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox®in the treatment of cervical dystonia
T. Odergren (1998)
10.1056/NEJM199104253241707
Therapeutic uses of botulinum toxin.
J. Jankovic (1991)
10.1097/DSS.0000000000000270
Botulinum toxin A for palmar hyperhidrosis: associated pain, duration, and reasons for discontinuation of therapy.
A. Kang (2015)
10.1111/ijd.12436
Scar prevention and remodeling: a review of the medical, surgical, topical and light treatment approaches
L. Kerwin (2014)
10.2147/CCID.S51938
Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports
S. Torres (2014)
10.1097/DSS.0000000000000277
Impact of Intradermal AbobotulinumtoxinA on Facial Erythema of Rosacea
B. Bloom (2015)
Practical applications of a new botulinum toxin.
D. Hexsel (2010)
10.1016/j.jaad.2008.12.028
Botox and Dysport: is there a dose conversion ratio in dermatology and aesthetic medicine?
S. Karsai (2010)
10.1097/PRS.0000000000001787
Anatomy of the Lower Face and Botulinum Toxin Injections
P. Trévidic (2015)
10.1111/j.1524-4725.2010.01473.x
Effects of Botulinum Toxin—A Therapy for Palmar Hyperhidrosis in Plantar Sweat Production
S. Gregoriou (2010)
Successful treatment of erythematotelangiectatic rosacea with pulsed light and radiofrequency.
A. Taub (2008)
10.1590/abd1806-4841.20143200
Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy*
F. H. M. D. S. Klein (2014)
10.1016/j.jaad.2013.02.013
The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial.
O. Ibrahim (2013)
Current and future botulinum neurotoxin type A preparations in aesthetics: a literature review.
G. Sattler (2010)
10.1007/s00266-006-0161-1
Reconstituted Botulinum Type A Neurotoxin: Clinical Efficacy After Long-Term Freezing Before Use
A. Parsa (2006)
10.1007/s10286-002-0026-x
The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A
V. Tugnoli (2002)
10.1128/AEM.72.2.1231-1238.2006
Detection of Type A, B, E, and F Clostridium botulinum Neurotoxins in Foods by Using an Amplified Enzyme-Linked Immunosorbent Assay with Digoxigenin-Labeled Antibodies
S. Sharma (2006)
10.1097/PRS.0b013e31825dc32f
A Simplified Method for Smile Enhancement: Botulinum Toxin Injection for Gummy Smile
Eduardo Sucupira (2012)
10.1016/J.JAAD.2005.06.011
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
T. Coté (2005)
10.1136/jnnp.2007.130138
Skin reactions after intramuscular injection of Botulinum toxin A: A rare side effect
N. Brüggemann (2008)
10.1097/DSS.0000000000000274
Patient-Reported Outcomes After IncobotulinumtoxinA Treatment for Upper Facial Wrinkles
M. Streker (2015)
10.1111/j.1524-4725.1998.tb04106.x
Complications of Botulinum A Exotoxin for Hyperfunctional Lines
S. Matarasso (1998)
10.1097/01.IOP.0000129012.09632.49
Increased Patient Comfort Utilizing Botulinum Toxin Type A Reconstituted with Preserved Versus Nonpreserved Saline
D. M. Kwiat (2004)
10.1111/j.1468-3083.2011.04066.x
Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double‐blind, randomized, comparative preliminary study
A. Güleç (2012)
10.1016/j.jaad.2011.01.009
State medical board regulation of minimally invasive cosmetic procedures.
Samreen Choudhry (2012)
10.1001/archfacial.2011.1650
Update on the effect of botulinum toxin pretreatment on laser resurfacing results.
M. Zimbler (2012)
10.1046/J.1524-4725.2001.01038.X
Botulinum‐A Toxin Treatment of the Lower Eyelid Improves Infraorbital Rhytides and Widens the Eye
T. Flynn (2001)
10.1007/s00702-013-0998-9
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm
D. Truong (2013)
10.1097/PRS.0000000000001750
Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck—Lower Face
Douglas C Wu (2015)
10.1111/jocd.12082
Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin
K. Beer (2014)
10.1097/PRS.0000000000001733
Neurotoxins: Expanding Uses of Neuromodulators in Medicine—Major Depressive Disorder
M. Magid (2015)
10.1038/sj.eye.6702465
Microbial growth in vials of Botulinum toxin following use in clinic
J. Menon (2007)
10.1111/j.1473-2165.2008.00395.x
Do different formulations of botulinum toxin type A really have different migration characteristics?
S. Karsai (2008)
10.1111/j.1524-4725.2011.02284.x
Pain Difference Associated with Injection of AbobotulinumtoxinA Reconstituted with Preserved Saline and Preservative‐Free Saline: A Prospective, Randomized, Side‐by‐Side, Double‐Blind Study
S. Allen (2012)
10.1177/0333102410364677
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. Diener (2010)
10.1016/j.coms.2008.11.001
Complications in fillers and Botox.
J. Niamtu (2009)
10.3109/00207454.2015.1019624
Botulinum toxin A in the treatment of trigeminal neuralgia
Jian-hua Xia (2016)
10.1016/J.FSC.2006.10.001
Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications.
G. Borodic (2007)
10.7916/D88W3C1M
Diffusion of Botulinum Toxins
M. Brodsky (2012)
10.1111/J.1524-4725.2006.32330.X
Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis.
A. R. Trindade de Almeida (2007)
10.1001/archfaci.10.4.273
Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox.
G. C. Yang (2008)
10.1111/j.1526-4637.2010.00897.x
Botulinum toxin A for treatment of allodynia of complex regional pain syndrome: a pilot study.
D. Safarpour (2010)
10.1016/j.anorl.2011.07.002
Botulinum toxin in the treatment of post-radiosurgical neck contracture in head and neck cancer: a novel approach.
C. Bach (2012)
10.1111/J.1399-6576.2007.01279.X
Anesthetic implications of botulinum toxin type A (Botox) injections for the treatment of ‘the aging face’ in the parturient
K. M. Kuczkowski (2007)
10.1097/DSS.0000000000000276
Safety and Efficacy of RT002, an Injectable Botulinum Toxin Type A, for Treating Glabellar Lines: Results of a Phase 1/2, Open-Label, Sequential Dose-Escalation Study
Enrique Garcia-Murray (2015)
10.1111/J.1524-4725.2005.31151
Effects of Botulinum Toxin Type A on Contouring of the Lower Face
Seong Wook Choe (2005)
10.1111/j.1526-4610.2011.02034.x
Atrophy of Corrugator Supercilii Muscle in a Patient Induced by the Onabotulinum Toxin Injection
Chonghao Zhao (2012)
10.1016/j.gtc.2014.11.010
Pyloric sphincter therapy: botulinum toxin, stents, and pyloromyotomy.
J. Clarke (2015)
10.1177/1090820X11434506
Treatment of hyperhidrosis with botulinum toxin.
Melissa A. Doft (2012)
10.1016/j.jpsychires.2013.11.006
Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial.
E. Finzi (2014)
10.1016/j.det.2014.06.013
Botulinum toxin for axillary hyperhidrosis.
A. R. D. de Almeida (2014)
10.1046/J.1524-4725.2003.29121.X
Multicenter, Double‐Blind Study of the Efficacy of Injections With Botulinum Toxin Type A Reconstituted Up to Six Consecutive Weeks Before Application
D. Hexsel (2003)
10.1111/1346-8138.12230
Local injection of botulinum toxin A: An alternative therapy for axillary osmidrosis
A. Xie (2014)
10.1111/jocd.12134
Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial
Eman Shaarawy (2015)
10.1016/j.urology.2009.05.097
Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity.
A. Sahai (2010)
10.1001/ARCHFACI.6.3.188
Botulinum toxin for masseter reduction in Asian patients.
Jeffrey M. Ahn (2004)
10.1111/j.1365-4632.2010.04821.x
Botulinum toxin historical aspects: from food poisoning to pharmaceutical
D. Kopera (2011)
10.2165/11584780-000000000-00000
Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
J. Frevert (2010)
10.1016/j.jaad.2013.12.035
Duration of efficacy increases with the repetition of botulinum toxin A injections in primary palmar hyperhidrosis: a study of 28 patients.
M. Lecouflet (2014)
10.1002/MDS.20440
Botulinum toxin and skin rash reaction
T. Mezaki (2005)
10.1212/01.WNL.0000055087.96356.BB
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia
J. Jankovic (2003)
10.1007/s00415-003-1129-6
Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure
D. Dressler (2003)
Cost effectiveness of botulinum toxins for the treatment of depression: preliminary observations.
K. Beer (2010)
10.1046/J.1524-4725.2003.29124.X
Botulinum Toxin Type B (MYOBLOC) Versus Botulinum Toxin Type A (BOTOX) Frontalis Study: Rate of Onset and Radius of Diffusion
T. Flynn (2003)
10.1002/MDS.20205
Botulinum toxin type A therapy during pregnancy
W. Newman (2004)
10.1136/jnnp.53.8.640
Botulinum toxin treatment in spasmodic torticollis.
J. Blackie (1990)
10.1111/j.1524-4725.2007.34061.x
Dermatologists Perform More Skin Surgery Than Any Other Specialist: Implications for Health Care Policy, Graduate and Continuing Medical Education
R. Roenigk (2008)
10.1097/DSS.0000000000000740
Rejuvenation of the Upper Face and Periocular Region: Combining Neuromodulator, Facial Filler, Laser, Light, and Energy-Based Therapies for Optimal Results
N. Langelier (2016)
10.1001/jamadermatol.2013.7117
Increased risk of litigation associated with laser surgery by nonphysician operators.
H. Jalian (2014)
10.5009/gnl14446
The Pathogenesis and Management of Achalasia: Current Status and Future Directions
F. Ates (2015)
10.1097/DSS.0000000000000275
Patient Satisfaction and Safety With Aesthetic OnabotulinumtoxinA After At Least 5 Years: A Retrospective Cross-Sectional Analysis of 4,402 Glabellar Treatments
A. R. Trindade de Almeida (2015)
10.1111/j.1524-4725.2010.01741.x
Comparison of Treatment of Melomental Fold Rhytides with Cross‐Linked Hyaluronic Acid Combined with OnabotulinumtoxinA and Cross‐Linked Hyaluronic Acid Alone
Trenton Custis (2010)
10.1080/09546630600899070
Botulinum toxin A treatment for contouring of the lower leg
Kwang-Ho Han (2006)
10.1097/DSS.0000000000000273
You Want to Inject What?
A. Carruthers (2015)
10.1067/MJD.2000.105567
Pharmacology of botulinum toxin.
W. Huang (2000)
10.1097/DSS.0000000000000162
Prolonging the Duration of Masseter Muscle Reduction by Adjusting the Masticatory Movements After the Treatment of Masseter Muscle Hypertrophy With Botulinum Toxin Type A Injection
J. Wei (2015)
10.1111/J.1524-4725.2006.32340.X
Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy.
Soo-Keun Lee (2007)
10.1111/ced.12362
Comparison of efficacy and diffusion of three formulations of botulinum toxin type A in two patients with forehead hyperhidrosis
E. Ko (2014)
10.1016/j.jaad.2009.06.040
Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants.
M. F. Brin (2009)
10.1001/ARCHDERM.143.11.1447-B
A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity.
S. Karsai (2007)
10.1139/M72-016
Thermal stability of the deoxyribonucleic acid hybrids between the proteolytic strains of Clostridium botulinum and Clostridium sporogenes.
J. Wu (1972)
Psoriasiform eruption from intramuscular botulinum A toxin.
J. Bowden (1992)
10.1016/j.toxicon.2015.06.003
Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions.
M. Atassi (2015)
10.1002/MUS.880170609
Elimination of superfluous neuromuscular junctions in rat calf muscles recovering from botulinum toxin–induced paralysis
S. M. Hassan (1994)
10.1097/DSS.0000000000000177
IncobotulinumtoxinA for the Treatment of Platysmal Bands: A Single-Arm, Prospective Proof-of-Concept Clinical Study
W. Prager (2015)
10.1016/J.AJIC.2007.10.007
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings
J. Siegel (2007)
Botulinum toxin type a versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis.
K. Flanagan (2008)
10.1111/J.1524-4725.2004.30253.X
Nonphysician Practice of Dermatologic Surgery: The Texas Perspective
P. Friedman (2004)
Attitudes, awareness, and usage of medical antiaging treatments: results of a patient survey.
S. Weinkle (2010)
10.1016/J.CLINDERMATOL.2003.12.025
Cosmetic uses of botulinum toxins for lower aspects of the face and neck.
N. Lowe (2004)
10.1002/MUS.880180708
Five‐year experience in the treatment of focal movement disorders with low‐dose dysportTM botulinum toxin
P. V. D. van den Bergh (1995)
10.1111/dsu.0000000000000016
Who Do You Prefer? A Study of Public Preferences for Health Care Provider Type in Performing Cutaneous Surgery and Cosmetic Procedures in the United States
H. Bangash (2014)
10.1046/j.1468-1331.2001.00261.x
Side‐effects of intradermal injections of botulinum A toxin in the treatment of palmar hyperhidrosis: a neurophysiological study
C. Swartling (2001)
10.1097/DSS.0000000000000340
Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment
A. Carruthers (2015)
10.1212/01.wnl.0000345968.05959.cf
Botulinum toxin for diabetic neuropathic pain
R. Yuan (2009)
10.1111/j.1524-4725.2011.02166.x
Current Methods Employed in the Prevention and Minimization of Surgical Scars
Austin Liu (2011)
10.3109/14764172.2011.613480
Intense pulsed light for the treatment of Rosacea and Telangiectasias
R. Kassir (2011)
10.1111/jocd.12059
Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin a injection alone: a split‐face, rater‐blinded, randomized control trial
Meghan I Dubina (2013)
10.1016/j.jconrel.2012.01.002
Facilitation of transcutaneous drug delivery and vaccine immunization by a safe laser technology.
Xinyuan Chen (2012)
10.1177/1090820X14527603
OnabotulinumtoxinA for the treatment of a "gummy smile".
Jessica S Suber (2014)
10.1097/01.PRS.0000061003.68203.56
Efficacy of Reconstituted and Stored Botulinum Toxin Type A: An Electrophysiologic and Visual Study in the Auricular Muscle of the Rabbit
M. Jabor (2003)
10.1111/j.1524-4725.1998.tb04097.x
Clinical Indications and Injection Technique for the Cosmetic Use of Botulinum A Exotoxin
A. Carruthers (1998)
10.1212/WNL.42.7.1307
Dysphagia after botulinum toxin injections for spasmodic torticollis
C. Comella (1992)
10.1111/J.1524-4725.1998.TB04093.X
Understanding Botulinum Toxin: Surgical Anatomy of the Frown, Forehead, and Periocular Region
J. Wieder (1998)
10.1111/j.1473-2165.2008.00361.x
Different formulations of botulinum toxin type A have different migration characteristics: a double‐blind, randomized study
S. Cliff (2008)
10.1046/j.1365-2133.2003.05593.x
A review of peripheral nerve blockade as local anaesthesia in the treatment of palmar hyperhidrosis
M. Hayton (2003)
10.1067/MJD.2003.487
Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial.
S. van Laborde (2003)
10.1111/jocd.12001
Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose‐conversion ratio for the treatment of glabellar frown lines
W. Prager (2012)
10.1097/01.IOP.0000217703.80859.A3
Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides.
Gary Borodic (2006)
Botulinum toxin type A enhances the outcome of fractional resurfacing of the cheek.
K. Beer (2007)
10.1111/j.1529-8019.2012.01455.x
Complications of injectable fillers and neurotoxins
S. E. Cox (2011)
10.1002/mds.20376
Long‐term botulinum toxin efficacy, safety, and immunogenicity
Nicte I. Mejia (2005)
10.1111/j.1468-1331.2006.01439.x
Immunological aspects of Botox®, Dysport® and MyoblocTM/NeuroBloc®
D. Dressler (2006)
10.1097/SCS.0b013e318292c80c
The Quantitative Effect of Botulinum Toxin A Over Brow Height
Ş. Uygur (2013)
10.1111/j.1524-4725.2010.01705.x
Multicenter, Randomized, Parallel‐Group Study of the Safety and Effectiveness of OnabotulinumtoxinA and Hyaluronic Acid Dermal Fillers (24‐mg/mL Smooth, Cohesive Gel) Alone and in Combination for Lower Facial Rejuvenation
A. Carruthers (2010)
10.1111/ijd.12200
The use of botulinum toxin‐A in the management of neck and anterior chest wall flushing: pilot study
E. Geddoa (2013)
10.1002/lsm.20860
Fractional CO2 laser‐assisted drug delivery
M. Hædersdal (2010)
10.1097/PRS.0b013e318170813c
Comparisons among Botulinum Toxins: An Evidence-Based Review
A. Klein (2008)
10.1002/MDS.870120627
DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1
C. Sampaio (1997)
10.4253/wjge.v7.i8.790
Endoscopic botox injections in therapy of refractory gastroparesis.
A. Ukleja (2015)
Neurotoxin waste from drawing product through the vial stopper.
Niamtu J rd (2014)
10.1053/MDA.2001.25964
Complications and adverse reactions with the use of botulinum toxin.
A. Klein (2002)
10.1016/j.jaad.2011.10.008
Recommendations and current practices for the reconstitution and storage of botulinum toxin type A.
Austin Liu (2012)
10.1016/j.jaad.2015.08.051
Botulinum toxin for depression: Does patient appearance matter?
J. Reichenberg (2016)
10.1080/09638280701568296
Pharmacology of therapeutic botulinum toxin preparations
D. Dressler (2007)
10.1046/j.1524-4725.2000.99278.x
Botulinum Toxin Type A for the Treatment of Axillary Hailey–Hailey Disease
J. C. Lapière (2000)
10.1016/S0039-6257(97)81995-9
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects.
J. Dutton (1996)
10.1111/dsu.0000000000000001
Efficacy of IncobotulinumtoxinA for Treatment of Glabellar Frown Lines: A Post Hoc Pooled Analysis of 2 Randomized, Placebo-Controlled, Phase 3 Trials
D. Jones (2014)
10.1097/PRS.0000000000001877
The Effect of Chemodenervation by Botulinum Neurotoxin on the Degradation of Hyaluronic Acid Fillers: An Experimental Study
Ismail Küçüker (2016)
10.1001/ARCHOTO.123.4.389
The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients.
A. Blitzer (1997)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar